Browse > Article
http://dx.doi.org/10.7469/JKSQM.2021.49.2.145

Development of a New Similarity Index to Compare Time-series Profile Data for Animal and Human Experiments  

Lee, Ye Gyoung (Department of Industiral & Management Systems Engineering, Dong-A University)
Lee, Hyun Jeong (Department of Industiral & Management Systems Engineering, Dong-A University)
Jang, Hyeon Ae (Department of Frontier Convergence Engineering, JEONJU University)
Shin, Sangmun (Department of Industiral & Management Systems Engineering, Dong-A University)
Publication Information
Abstract
Purpose: A statistical similarity evaluation to compare pharmacokinetics(PK) profile data between nonclinical and clinical experiments has become a significant issue on many drug development processes. This study proposes a new similarity index by considering important parameters, such as the area under the curve(AUC) and the time-series profile of various PK data. Methods: In this study, a new profile similarity index(PSI) by using the concept of a process capability index(Cp) is proposed in order to investigate the most similar animal PK profile compared to the target(i.e., Human PK profile). The proposed PSI can be calculated geometric and arithmetic means of all short term similarity indices at all time points on time-series both animal and human PK data. Designed simulation approaches are demonstrated for a verification purpose. Results: Two different simulation studies are conducted by considering three variances(i.e., small, medium, and large variances) as well as three different characteristic types(smaller the better, larger the better, nominal the best). By using the proposed PSI, the most similar animal PK profile compare to the target human PK profile can be obtained in the simulation studies. In addition, a case study represents differentiated results compare to existing simple statistical analysis methods(i.e., root mean squared error and quality loss). Conclusion: The proposed PSI can effectively estimate the level of similarity between animal, human PK profiles. By using these PSI results, we can reduce the number of animal experiments because we only focus on the significant animal representing a high PSI value.
Keywords
PK profile; Profile similarity index; Human and animal experiments;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kang WH., Hwang JA., Chae JW., Kwon KI., and Yun HY. 2019. The Role Change of Drug Metabolism and Pharmacokinetics Research in the Drug Development. Yakhak Hoeji 63(3):121-130.   DOI
2 KFDA. 2011. Bioequivalence Test Professional Education Manual.
3 Kola I., Landis J. 2004. Can the Pharmaceutical Industry Reduce Rates?. Nature Reviews Drug Discovery 3(8):711-6.   DOI
4 Lee DK. 2016. Analysis of Process Capability Index for Multiple Measurements. Journal of Society of Korea Industrial and Systems Engineering 39(1):91-7.   DOI
5 Lee YJ., Kim YG., Lee MG., Chung SJ., Lee MH., and Shim CK. 2000. Analysis of Bioequivalence Study using a Log-transformation Model. Yakhak Hoeji 44(4):308-14.
6 Mahalanobis PC. 1936. On the Generalized Distance in Statistics. National Institute of Sciences of India 2(1):49-55.
7 Prueksaritanont T., Tang C. 2012. ADME of Biologics-What Have We Learned from Small Molecules?. The AAPS Journal 14(3):410-9.   DOI
8 Shin DS. 2016. Study on Estimated Methods for Parmacokinetics Profiles of Drugs Discovery. MS diss., Dong-A University.
9 Lee HJ. 2020. Study on a Similarity Index of the Pharmacokinetic Profiles for Clinical and Nonclinical Trials. MS diss., Dong-A University.
10 Brereton RG. 2015. The Mahalanobis Distance and its Relationship to Principal Component Scores. Journal of Chemometrics 29(3):143-5.   DOI
11 Chan LK., Cheng SW., and Spiring F. 1988. A New Measure of Process Capability: Cpm. Journal of Quality Technology 20(3):162-175.   DOI
12 De Maesschlck R., Jouan-Rimbaud D., and Massart DL. 2000. The Mahalanobis Distance. Chemometrics and Intelligent Laboratory Systems 50(1):1-18.   DOI
13 DiMasi JA., Feldman L., Seckler A., and Wilson A. 2010. Trends in Risks Associated with New Drug Development: Success Rates for Investigational Drugs. Clionical Pharmacology & Therapeutics 87(3):272-7.   DOI
14 Gnanadesikan R., Kettenring JR. 1972. Robust Estimates, Residuals, and Outlier Detection with Multiresponse Data. Biometrics:81-124.
15 Jung JH. 2018. A Study on Similarity Evaluation Methodologies for Identifying the Correlation between Clinical and Nonclinical Trials on a Pharmaceutical Formulation Development. MS diss., Dong-A University.